Abstract

Nagilactone E, an antifungal agent derived from the root bark of Podocarpus nagi, inhibits 1,3-β glucan synthesis; however, its inhibitory activity is weak. Anethole, the principal component of anise oil, enhances the antifungal activity of nagilactone E. We aimed to determine the combinatorial effect and underlying mechanisms of action of nagilactone E and anethole against the budding yeast Saccharomyces cerevisiae. Analyses using gene-deficient strains showed that the multidrug efflux pump PDR5 is associated with nagilactone E resistance; its transcription was gradually restricted in cells treated with the drug combination for a prolonged duration but not in nagilactone-E-treated cells. Green-fluorescent-protein-tagged Pdr5p was intensively expressed and localized on the plasma membrane of nagilactone-E-treated cells but not in drug-combination-treated cells. Quick-freeze deep-etch electron microscopy revealed the smoothening of intertwined fiber structures on the cell surface of drug-combination-treated cells and spheroplasts, indicating a decline in cell wall components and loss of cell wall strength. Anethole enhanced the antifungal activity of nagilactone E by enabling its retention within cells, thereby accelerating cell wall damage. The combination of nagilactone E and anethole can be employed in clinical settings as an antifungal, as well as a food preservative to restrict food spoilage.

Highlights

  • Antibiotics and preservatives used in food items should have minimal side effects in humans and target microbes

  • The fractional inhibitory concentration (FIC) indices for all C. albicans strains were less than 0.5625, indicating weak synergistic effects

  • These results suggest that fluconazole resistance does not affect the synergistic antifungal activity of the drug combination

Read more

Summary

Introduction

Antibiotics and preservatives used in food items should have minimal side effects in humans and target microbes. Fungi, including molds and yeasts, are eukaryotes and have metabolic processes and cell structures similar to those of humans, which makes the development of targeted treatment options against fungal pathogens a challenge. Drug-resistant fungi need to be controlled using new drugs or combination therapy. Resistance of fungal cells to a drug can be overcome using another drug that suppresses this resistance. Nagilactone C, D, and F have insect feeding deterrent activity against Lactuca sativa [3]. Nagilactone E exhibits antifungal activity against Candida albicans, Pityrosporium ovale, and the budding yeast Saccharomyces cerevisiae [8]. As the activity is relatively weaker than that of other available antifungal drugs, such as micafungin and fluconazole [10], other drugs can be used in combination with nagilactone E to enhance its antifungal activity

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call